Member Info for Chazzy2

Don't you ever sleep Snoots? You're not allergic to garlic and mirrors are you?

https://www.cleanroomtechnology.com/news/article_page/Cannabis_Europa_2019_puts_CBD_in_the_spotlight/155560

Yes it's a difficult one knowing what's best. I would be inclined to hold on for now and wait and see if Portage list on a more liquid market, in which case you may not need to transfer, unless you're in a real hurry to sell.
I was curious to know how I could sell my Portage shares if I needed to but I'm inclined now to wait and see how it pans out. Must admit I haven't read about the consolidation idea but I certainly wouldn't do anything to risk losing any shares.

Cheers Bod. Will probably hang on for a bit then.

They don't seem to RNS investee company news these days unless it has some bearing the FFWD cash position. But even if they did RNS the Emmac news I doubt whether it would impact on the share price positively. There's a persistent bear out there with a serious weed (not the Emmac kind) up his posterior unloading for some reason.
I still believe in the fundamentals though. Emmac alone when it IPOs could add NAV equivalent to our current market cap. We're ridiculously undervalued right now but also at a serious inflexion point if you compare NAV to market cap.

Does anyone know of any uk brokers which do CREST dealing of Portage shares? Cheers!

Emmac building nicely.

Just realised it's the same as the RNS a while back. Don't know why Contract Pharma are so slow in reporting it!

https://www.contractpharma.com/contents/view_breaking-news/2019-06-13/intensity-therapeutics-receives-ftd-for-breast-cancer-treatment/

https://www.contractpharma.com/contents/view_breaking-news/2019-06-13/intensity-therapeutics-receives-ftd-for-breast-cancer-treatment/

Interesting interview with Jay Smith. I like the fact that he said that Factom hopes to have series B closed in the near future, although he didn't specify why the delay. He also said that Factom is extremely well known within the blockchain industry, and Factom does not really have any blockchain competitors, as Factom has a data-centric business model, whereas most of the others are coin-centric.

https://www.businesswire.com/news/home/20190610005438/en/Announces-Acquisition-French-Wellness-Company-GreenLeaf

https://vimeo.com/253656312

This video is a few months old but gives a great (if slightly technical) introduction to Lygenesis. Phase 2 trials to start next year, skipping phase 1 altogether such is the need for this technology. Huge potential and Juvenescence owns 30%.

https://www.eurekalert.org/pub_releases/2019-06/imi-imu060619.php

Chils, that's a sensible post. The only thing I would add though is that Intensity probably has a better chance of success than your average private company developing a new cancer drug, for the following reasons:
Intensity's approach is not to trial a new drug, but to take proven chemotherapy drugs and deliver them in a much more effective way directly to the tumour, which results in fewer side effects, thoroughly destroys the tumour and stimulates an immune response. Safety does not appear to be an issue so it's just a question of how effective the treatment is at higher doses, but so far it's looking very promising, even at low doses.

Leap upon sale/IPO and Emmac upon IPO could each be worth our current market cap. Intensity could be multiples upon a buy out if results continue to be good. Then there's Factom, Juvenescence, and Regent Pacific (if the deal goes through) each with enormous potential long term.
There seems to be a gradual trend towards FFWD investing in life-science funds which reduces risk but maintains focus on the huge longevity and wellness market. Bargain price at present.

https://player.fm/series/the-bio-report-49047/a-treat-locally-act-globally-strategy-for-treating-cancer

After another sh-tty week for the share price here is an interview which may just restore you faith in FFWD. This could be the investment which finally blows the sp out of the water.
It's a few weeks old now but Lew Bender of Intensity gives this really inspiring interview, as well as hope to millions!

https://www.prnewswire.co.uk/news-releases/regent-pacific-enters-exploding-cbd-market-in-asia-through-proposed-acquisition-of-yooya-882370972.html

Now it's had time to sink in it's looking very interesting indeed and the overall picture is becoming clearer.
Also if you really believe in the Yooya story, there is RP you can invest in directly now for 100% of Yooya.

On the face of it it's a disappointing valuation for Yooya considering all the 'YouTube' analogy rhetoric, but trying to put a positive spin on things, if the deal does go through we'll have more control over exiting, and in the meantime we take on Plethora as a new investment also which adds to the Life Science mix. Let's hope there is least one unicorn left amongst our portfolio.

Cheers for the tip Jesterman.